{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"51.9","upperLimit":"95.7","value":"80"},{"groupId":"OG001","lowerLimit":"34.9","upperLimit":"96.8","value":"75"},{"groupId":"OG002","lowerLimit":"35.9","upperLimit":"99.6","value":"83.3"},{"groupId":"OG003","lowerLimit":"49.8","upperLimit":"86.2","value":"70.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"27"}],"units":"Participants"}],"description":"ORR was defined as the percentage of participants who achieved a best confirmed response of Partial Response (PR) or better.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were administered IV melflufen at a dose of 30 mg on Day 1 of each 28-day cycle in combination with SQ bortezomib at a dose of 1.3mg/m\\^2 on Days 1, 4, 8, and 11 and dexamethasone PO at a dose of 20 mg (12 mg if the participants is ≥ 75 years of age) on Days 1, 4, 8, and 11 and 40 mg (20 mg if the participants is ≥ 75 years of age) on Day 15 and 22 of each 28-day cycle.","id":"OG000","title":"Regimen A - Melflufen 30mg + Bortezomib + Dexamethasone"},{"description":"Participants were administered IV melflufen at a dose of 40 mg on Day 1 of each 28-day cycle in combination with SQ bortezomib at a dose of 1.3mg/m\\^2 on Days 1, 4, 8, and 11 and dexamethasone PO at a dose of 20 mg (12 mg if the participants is ≥ 75 years of age) on Days 1, 4, 8, and 11 and 40 mg (20 mg if the participants is ≥ 75 years of age) on Day 15 and 22 of each 28-day cycle.","id":"OG001","title":"Regimen A - Melflufen 40mg + Bortezomib + Dexamethasone"},{"description":"Participants were administered IV melflufen at a dose of 30 mg on Day 1 of each 28-day cycle in combination with IV daratumumab at a dose of 16 mg/kg weekly for 8 doses, every other week for 8 doses and then once every 4 weeks. Participants were also administered dexamethasone orally (PO) at a dose of 40 mg weekly (20 mg weekly if the participants is ≥ 75 years of age).","id":"OG002","title":"Regimen B - Melflufen 30mg + Daratumumab + Dexamethasone"},{"description":"Participants were administered IV melflufen at a dose of 40 mg on Day 1 of each 28-day cycle in combination with IV daratumumab at a dose of 16 mg/kg weekly for 8 doses, every other week for 8 doses and then once every 4 weeks. Participants were also administered dexamethasone orally (PO) at a dose of 40 mg weekly (20 mg weekly if the participants is ≥ 75 years of age).","id":"OG003","title":"Regimen B - Melflufen 40mg + Daratumumab + Dexamethasone"}],"paramType":"NUMBER","populationDescription":"All participants included in the Safety Analysis Set were included in this analysis.","reportingStatus":"POSTED","timeFrame":"Until disease progression, death or initiation of subsequent therapy (a maximum of 194.3 weeks)","title":"Phase 2: Overall Response Rate (ORR)","type":"PRIMARY","unitOfMeasure":"percentage of participants"}